Search Results
Your search for The A matches 31879 pages
Showing 2601 - 2650Germline Variants in Colorectal Cancer Susceptibility Genes by Race/Ethnicity in Patients With Early-Onset Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Seagle et al identified the prevalence of germline colorectal cancer susceptibility gene variants according to race and ethnicity among patients with early-onset colorectal cancer. Study Details The study involved patients aged 15 to 49 years ...
Prevalence of Prior Cancer Among Patients With Newly Diagnosed Cancer
In an analysis of Surveillance, Epidemiology, and End Results (SEER) data reported in a research letter in JAMA Oncology, Caitlin C. Murphy, PhD, MPH, and colleagues found that a substantial proportion of patients diagnosed with an incident cancer in 2019 had a history of prior cancer diagnosis....
Second-Line Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer
In a Korean phase Ib/II trial reported in the Journal of Clinical Oncology, Kim et al found that trastuzumab combined with ramucirumab and paclitaxel showed activity in the second-line treatment of patients with HER2-positive advanced gastric or gastroesophageal junction cancer whose disease...
Expert Point of View: Erminia Massarelli, MD, PhD, MS
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Novel HPV-Targeted Agents Boost Efficacy of Pembrolizumab in Head and Neck Cancer, Two Studies Show
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
Goals of Care in Primary Myelofibrosis
This is Part 3 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. In this video, Dr. Naveen Pemmaraju and Dr. Gabriela Hobbs discuss goals of care in primary myelofibrosis. The patient is a 27-year-old woman who presents to the clinic after 6 months of...
I Didn’t Want My Past to Become My Future
When I felt a large mass in my left breast as I was drying off from a shower on Thanksgiving Day, in 2007, I instinctively knew it was cancer. My mother had been diagnosed with breast cancer when she was 38, just 7 years older than I was at the time, and died 4 years later. I was 6 when she was...
Targeting Depressive Symptoms in Younger Breast Cancer Survivors
Guest Editor’s Note: Psychological distress is highly prevalent in women diagnosed with premenopausal breast cancer and has a significant negative impact on their quality of life. Thus, effective strategies are urgently needed to reduce the symptom burden. In this installment of The ASCO Post’s...
Retrospective View of Medical Dissection From May 1896
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Assessing Geriatric Oncology Practice in Portugal
The global population is aging rapidly. Currently, there are more than 703 million people worldwide aged 65 and older, representing 9.1% of the global population. It is estimated that this percentage will grow to 15.9%—1.5 billion people—by 2050.1 And with that growing aging population will come...
Sara Hurvitz, MD, Joins Fred Hutch, University of Washington, Seattle
On August 1, 2023, Sara Hurvitz, MD, will assume the role of Senior Vice President of the Clinical Research Division at Fred Hutch and as Head of the newly united Division of Hematology and Oncology at the University of Washington Department of Medicine in Seattle. Dr. Hurvitz will report directly...
Olaparib With Abiraterone and Prednisone or Prednisolone for BRCA-Mutated, Metastatic Castration-Resistant Prostate Cancer
On May 31, 2023, the PARP inhibitor olaparib was approved by the U.S. Food and Drug Administration (FDA) with abiraterone and prednisone or prednisolone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.1...
Epcoritamab-bysp in Treatment of Relapsed or Refractory B-Cell Lymphomas
On May 19, 2023, epcoritamab-bysp was granted accelerated approval by the U.S. Food and Drug Administration for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two ...
ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...
How ASCO’s 2023 Breakthrough Meeting Is Putting a Spotlight on Cutting-Edge Advances in Cancer Care Technology and Innovation
After a 4-year hiatus because of the COVID-19 pandemic, ASCO’s Breakthrough meeting is returning to Asia from August 3–5, 2023, in Yokohama, Japan, and will also be livestreamed (https://conferences.asco.org/breakthrough/welcome). Launched in 2019 in Bangkok, Thailand, “Breakthrough is ASCO’s...
A Telephone-Based Weight-Loss Intervention Induced Clinically Meaningful Weight Loss in Patients With Breast Cancer and Overweight or Obesity
Jennifer A. Ligibel, MD, FASCO, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and colleagues conducted a randomized study to evaluate the impact of a telephone-based ...
Health Systems Strengthening Approach in the United States–Mexico Border Region Improved 5-Year Survival for Children With ALL
The implementation of a collaborative program between North American and Mexican medical institutions to achieve sustainable, high-quality care at a public hospital in the United States–Mexico border region for children with acute lymphoblastic leukemia (ALL) has resulted in significant improvement ...
Expert Point of View: Caron Jacobson, MD
Caron Jacobson, MD, shared some comments on ZUMA-7 with The ASCO Post. She called ZUMA-7 “an extremely important study to advance the care of high-risk early relapsing or primary refractory large B-cell lymphoma after front-line chemoimmunotherapy.” Dr. Jacobson is Assistant Professor of Medicine...
Second Annual Conference at the Nixon Presidential Library and Museum Emphasizes Patients’ Concerns
On December 23, 1971, President Richard Nixon signed the National Cancer Act of 1971 into law, establishing a national cancer program that included the National Cancer Institute (NCI), other research institutes, and federal and nonfederal programs; funding for 15 new cancer research centers and...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
A European Leader in Surgical Oncology, Isabel T. Rubio, MD, PhD, Shares Her Story and Sheds Light on the Challenges Ahead
In this installment of The ASCO Post’s Global Oncology series, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Isabel T. Rubio, MD, PhD, Head of Breast Surgical Oncology at Clinica Universidad de Navarra, Madrid. Dr. Rubio is active in many societies and is a founding member and...
Expert Point of View: David A. Braun, MD, PhD
David A. Braun, MD, PhD, of Yale Cancer Center, was the formal discussant of the abstract on the 4-year follow-up of the CLEAR trial. “We have made remarkable progress [in advanced renal cell carcinoma] and are now in the combination era of immunotherapy-based therapy and immunotherapy-based...
Addition of Tislelizumab to Chemotherapy Improves Survival in Treatment of Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Jianming Xu, MD, of Fifth Medical Center, Chinese PLA General Hospital, Beijing, corresponding author Harry H. Yoon, MD, of the Department of Oncology, Mayo Clinic, Rochester, and colleagues, an interim analysis of the phase III RATIONALE-306 trial has shown...
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
Pathology Assessment During Mastectomy and Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer
Axillary management decisions made during surgery may be associated with aggressive treatment of limited nodal disease, according to data presented at a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Results of a large National Cancer Database study revealed that...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
Expert Point of View: Ann S. LaCasce, MD, MMSc
Formal discussant of the SWOG S1826 abstract, Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, Boston, said she was “excited” by these results. “The data speak for themselves. Nivolumab plus AVD [doxorubicin, vinblastine, dacarbazine] should be the treatment of choice, with more...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Expert Point of View: Mark Awad, MD, PhD
Formal discussant of KEYNOTE-671, Mark Awad, MD, PhD, of the Dana-Farber Cancer Institute, Boston, was optimistic about these data. “A hazard ratio of 0.58 for event-free survival and signals favoring overall survival in stage II to III non–small cell lung cancer [NSCLC] are truly impressive....
KEYNOTE-671 Trial: Perioperative Pembrolizumab Plus Chemotherapy Improves Outcomes in Stage II and III NSCLC
Neoadjuvant therapy with pembrolizumab plus platinum-based chemotherapy followed by surgery and then adjuvant pembrolizumab led to significantly improved event-free survival in patients with resectable stage II and III non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
A Call for Tailored Medical Services in Oncology Care for Older Deaf Patients
My father is deaf. Born deaf, he is now 75 years old. He uses his voice, but he sounds strange to a hearing person when he speaks. He uses lip-reading techniques to communicate. A year ago, he was diagnosed with Hodgkin lymphoma. We did his oncology itinerary together. My father cannot go alone to...
Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD
Commenting at a press briefing, Pamela L. Kunz, MD, Director of the Center for Gastrointestinal Cancers and Chief of GI Medical Oncology at Smilow Cancer Hospital and Yale Cancer Center, New Haven, said the results of PROSPECT are “practice-changing” and “align incredibly well with the theme at...
PROSPECT Trial: Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer
Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT...
Expert Point of View: Benjamin J. Solomon, MBBS, PhD
“Outcomes for patients with early-stage non–small cell lung cancer [NSCLC] remain poor despite potentially curative surgery and adjuvant cisplatin-based chemotherapy,” said formal abstract discussant Benjamin J. Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre and the University of Melbourne....
Adjuvant Osimertinib Improves Overall Survival in Resectable EGFR-Mutated NSCLC
The phase III ADAURA trial previously found that adjuvant use of osimertinib improved disease-free survival for completely resected EGFR-mutated non–small cell lung cancer (NSCLC) in patients with stage IB, II, or IIIA disease.1 The final analysis of ADAURA, which was presented at the 2023 ASCO...
Intracranial Activity of Adagrasib in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
In an analysis reported in the Journal of Clinical Oncology, Negrao et al identified outcomes in the KRYSTAL-1 trial among patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC) who had untreated central nervous system (CNS) metastases at baseline and were treated with...
Cancer Mortality Trends Among U.S. Hispanic Populations From 1999 to 2020
In a cross-sectional study reported in JAMA Oncology, Pompa et al found that overall cancer-specific mortality among U.S. Hispanic populations decreased between 1999 and 2020; however, mortality from some cancer types increased in the populations over this period. Study Details The study used data...
Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer
In a Korean study reported in the Journal of Clinical Oncology, Jin et al found that increased alcohol intake may be associated with an increased risk of early-onset colorectal cancer. Study Details The study involved data from 5,666,576 individuals aged 20 to 49 years from the Korean National...
Investigators Evaluate the Role of BMI in Outcomes in Patients With Head and Neck Cancer
Investigators have found that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those with a normal or obese BMI, according to a new study published...
Robotic-Assisted Resection of Challenging Gastric GISTs May Be Safe and Effective
Robot-assisted resection may be safe and effective at removing difficult-to-reach gastric gastrointestinal stromal tumors (GISTs), according to a novel study published by Lwin et al in the Journal of Surgical Research. Background For gastric GISTs, surgery is the standard treatment option; however, ...
Medicaid Expansion May Be Linked to Increase in Palliative Care for Patients With Advanced Cancers
The expansion of Medicaid coverage under the Affordable Care Act may be associated with the largest increases in critical palliative care services for patients with advanced cancers in the United States, according to a new study published by Han et al in Health Affairs. The findings uncovered how...
Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept
Aaron T. Gerds, MD, of Cleveland Clinic Taussig Cancer Institute, talks about treating the anemia many patients with myelofibrosis experience because of JAK inhibitor therapy. The ACE-536-MF-001 study showed that luspatercept improved anemia and transfusion burden in this population, with a safety...
First-Line FOLFOXIRI Plus Cetuximab or Bevacizumab in BRAF V600E–Mutant Metastatic Colorectal Cancer
In the German phase II FIRE-4.5 trial reported in the Journal of Clinical Oncology, Stintzing et al found that the addition of cetuximab vs bevacizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) did not improve objective response rate in the first-line treatment of...
Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
Addition of Relacorilant to Nab-paclitaxel in Recurrent, Platinum-Resistant Ovarian Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Nicoletta Colombo, MD, and colleagues found that the selective glucocorticoid receptor modulator relacorilant (given on an intermittent schedule) plus nab-paclitaxel showed benefits vs nab-paclitaxel alone in patients with recurrent, ...
COVID-19 Booster Doses May Strengthen Immunity in Patients With Lymphoma
Researchers have found that repeated COVID-19 vaccination may increase the vaccine’s effectiveness at preventing the infections in patients with lymphoma, particularly after four doses, according to a new study published by Wijaya et al in The Lancet. Background Patients with lymphoma often have...
